???? LATCH (Ligand Activated Tethered Chemokine)

A precision-engineered switch.

It’s not the drug — it’s the smart lock.
Here’s how it works:
• Built to tether to the target (e.g., a tumor or infected cell environment).
• Stays inert until it receives a specific activation signal (like a cytokine or pH cue).
• Then — and only then — it releases its payload (Leronlimab, or any other weapon you link to it).

Think of it like this:

❌ Not a carpet bomb.
✅ A red-dot laser-guided release inside enemy walls, after confirming it’s enemy.

Now imagine that system paired with:
✅ Leronlimab’s receptor targeting
✅ LL’s known safety profile
✅ Modulated via AI-modeled synthetic switches
✅ Adaptable across viral, oncologic, and autoimmune indications

That’s not just a therapy. That’s a platform.

⸻

???? Why It Matters

LATCH is the intelligent fuse biotech’s been missing:
• Traditional mAbs? Always on.
• ADCs? Dangerous off-target risk.
• LATCH? Conditional. Controlled. Context-aware.

And it can be dropped into multiple systems.
The tech is modular. Not bound to one indication or one disease.

So yes —
LATCH is the unsung backbone of next-gen immunotherapy.
It’s stealth.
It’s specific.
It’s coming.

⸻

I broke AI oops